A detailed history of Pdt Partners, LLC transactions in Agios Pharmaceuticals, Inc. stock. As of the latest transaction made, Pdt Partners, LLC holds 56,735 shares of AGIO stock, worth $3.16 Million. This represents 0.25% of its overall portfolio holdings.

Number of Shares
56,735
Previous 75,280 24.63%
Holding current value
$3.16 Million
Previous $3.25 Million 22.37%
% of portfolio
0.25%
Previous 0.33%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$41.19 - $49.72 $763,868 - $922,057
-18,545 Reduced 24.63%
56,735 $2.52 Million
Q2 2024

Aug 15, 2024

SELL
$27.55 - $48.83 $499,316 - $884,994
-18,124 Reduced 19.4%
75,280 $3.25 Million
Q1 2024

May 15, 2024

BUY
$21.32 - $34.81 $175,911 - $287,217
8,251 Added 9.69%
93,404 $2.73 Million
Q4 2023

Feb 14, 2024

BUY
$19.97 - $24.53 $777,851 - $955,468
38,951 Added 84.31%
85,153 $1.9 Million
Q3 2023

Nov 14, 2023

BUY
$24.36 - $28.18 $68,013 - $78,678
2,792 Added 6.43%
46,202 $1.14 Million
Q2 2023

Aug 14, 2023

BUY
$21.38 - $29.19 $367,586 - $501,863
17,193 Added 65.58%
43,410 $1.23 Million
Q1 2023

May 15, 2023

SELL
$21.74 - $30.93 $813,249 - $1.16 Million
-37,408 Reduced 58.79%
26,217 $602,000
Q4 2022

Feb 14, 2023

SELL
$24.81 - $31.52 $227,085 - $288,502
-9,153 Reduced 12.58%
63,625 $1.79 Million
Q3 2022

Nov 14, 2022

SELL
$19.51 - $34.14 $853,640 - $1.49 Million
-43,754 Reduced 37.55%
72,778 $2.06 Million
Q2 2022

Aug 15, 2022

BUY
$17.06 - $31.42 $1.44 Million - $2.65 Million
84,258 Added 261.07%
116,532 $2.58 Million
Q1 2022

May 16, 2022

BUY
$26.68 - $34.81 $861,070 - $1.12 Million
32,274 New
32,274 $939,000
Q2 2021

Aug 16, 2021

SELL
$52.06 - $61.27 $3.73 Million - $4.39 Million
-71,700 Closed
0 $0
Q1 2021

May 17, 2021

SELL
$44.23 - $57.5 $1.81 Million - $2.35 Million
-40,878 Reduced 36.31%
71,700 $3.7 Million
Q4 2020

Feb 16, 2021

BUY
$33.21 - $46.54 $208,492 - $292,178
6,278 Added 5.91%
112,578 $4.88 Million
Q3 2020

Nov 16, 2020

BUY
$33.87 - $55.93 $992,390 - $1.64 Million
29,300 Added 38.05%
106,300 $3.72 Million
Q2 2020

Aug 14, 2020

SELL
$34.45 - $53.48 $531,701 - $825,410
-15,434 Reduced 16.7%
77,000 $4.12 Million
Q1 2020

May 15, 2020

SELL
$31.52 - $53.81 $91,344 - $155,941
-2,898 Reduced 3.04%
92,434 $3.28 Million
Q4 2019

Feb 14, 2020

BUY
$30.08 - $50.59 $668,738 - $1.12 Million
22,232 Added 30.41%
95,332 $4.55 Million
Q3 2019

Nov 14, 2019

SELL
$32.4 - $49.58 $680 - $1,041
-21 Reduced 0.03%
73,100 $2.37 Million
Q2 2019

Aug 14, 2019

BUY
$46.17 - $68.1 $3.38 Million - $4.98 Million
73,121 New
73,121 $3.65 Million
Q3 2018

Nov 14, 2018

SELL
$71.67 - $91.95 $4.74 Million - $6.09 Million
-66,200 Closed
0 $0
Q2 2018

Aug 14, 2018

SELL
$73.22 - $99.55 $3.21 Million - $4.36 Million
-43,836 Reduced 39.84%
66,200 $5.58 Million
Q1 2018

May 15, 2018

SELL
$59.83 - $86.53 $2.47 Million - $3.57 Million
-41,232 Reduced 27.26%
110,036 $9 Million
Q4 2017

Feb 14, 2018

SELL
$52.12 - $72.33 $1.82 Million - $2.52 Million
-34,833 Reduced 18.72%
151,268 $8.65 Million
Q3 2017

Nov 14, 2017

BUY
$54.89 - $67.12 $10.2 Million - $12.5 Million
186,101
186,101 $12.4 Million

Others Institutions Holding AGIO

About AGIOS PHARMACEUTICALS, INC.


  • Ticker AGIO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 54,818,000
  • Market Cap $3.05B
  • Description
  • Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and ...
More about AGIO
Track This Portfolio

Track Pdt Partners, LLC Portfolio

Follow Pdt Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pdt Partners, LLC with notifications on news.